

INTERNATIONAL SCIENTIFIC JOURNAL

SCIENCE AND INNOVATION

VOLUME 4 / ISSUE 2

D ● BIOLOGY
● AGRICULTURE
● MEDICINE
● PHARMACETICS
● VETERINARY

FEBRUARY 2025



International Scientific Journal
SCIENCE AND INNOVATION
Series D
Volume 4 Issue 2
February 2025

Tashkent 2025

CLINICAL MANIFESTATIONS AND OUTCOMES OF COVID-19 IN PEDIATRIC POPULATIONS: A COMPREHENSIVE REVIEW

M.S. Akbarova¹

Tashkent Pediatric Medical Institute¹

<https://doi.org/10.5281/zenodo.14973807>

Abstract. *The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has affected populations worldwide, with children demonstrating a range of symptoms from mild to severe. Although children generally experience less severe manifestations of COVID-19 compared to adults, the emergence of serious complications such as Multisystem Inflammatory Syndrome in Children (MIS-C) has raised concern. This study aims to review the clinical features, treatment protocols, and outcomes of COVID-19 in pediatric populations, based on data gathered from multiple healthcare facilities. Through analysis of clinical data, we assess the prevalence of severe manifestations, risk factors, and long-term effects in children. The findings emphasize the importance of early detection, management strategies, and vaccination to mitigate the risks of severe disease.*

Keywords: *COVID-19, Pediatric COVID-19, SARS-CoV-2, Multisystem Inflammatory Syndrome (MIS-C), Pediatric outcomes, Hospitalization, Vaccination, Long COVID.*

Introduction

The emergence of the novel coronavirus (SARS-CoV-2) in December 2019 rapidly escalated into a global pandemic, causing significant morbidity and mortality. Although much of the focus during the initial phase of the pandemic was on adult populations, especially the elderly and those with pre-existing conditions, children were not immune to the virus. Initially, it was believed that children were less susceptible to severe disease, and this observation was supported by early epidemiological data. However, as the pandemic progressed, it became evident that some pediatric cases could result in severe complications, including respiratory failure and cardiovascular issues, with Multisystem Inflammatory Syndrome in Children (MIS-C) emerging as a major concern.

The purpose of this study is to evaluate the clinical presentation, outcomes, and complications of COVID-19 in children. By reviewing data from multiple healthcare institutions, we aim to provide a comprehensive overview of how the virus affects pediatric populations, the factors contributing to severe cases, and the best practices for clinical management.

Materials and Methods

This study is a systematic review and retrospective analysis based on clinical data from various hospitals and healthcare systems worldwide, focusing on children aged 0-18 years who were diagnosed with COVID-19 between 2020 and 2024. The data was obtained from hospital records, national health databases, and peer-reviewed journals.

Inclusion Criteria

- Children aged 0 to 18 years
- Positive SARS-CoV-2 test (PCR, antigen, or antibody)

- Presence or absence of clinical symptoms
- Data on comorbidities, treatments, and outcomes
- Hospitalization data and intensive care unit (ICU) admissions

Exclusion Criteria

- Children with incomplete medical records
- Children diagnosed with COVID-19 post-mortem
- Studies with unclear or incomplete data on disease severity or treatment outcomes

Statistical Analysis

Data from hospital records were compiled into a central database, and statistical methods were applied to determine correlations between variables such as age, comorbidities, severity of illness, and outcomes. The data was analyzed using chi-square tests for categorical variables and t-tests for continuous variables.

Results and Discussion

Clinical Features of COVID-19 in Children


Children generally exhibit a mild course of COVID-19, with most cases being asymptomatic or presenting with mild symptoms such as fever, cough, sore throat, and fatigue. However, recent studies have identified several factors that contribute to the severity of the disease in children, such as the presence of underlying health conditions like asthma, obesity, and immunodeficiencies.

Table 1: Common Symptoms in Pediatric COVID-19 Cases

Symptom	Percentage of Cases(%)
fever	55%
cough	45%
Sore throat	20%
fatigue	25%
Shortness of breath	12%
Asymptomatic	30%
Diarrhea	7%

In general, fever is the most common symptom observed, followed by a cough and fatigue. The incidence of severe respiratory distress in children remains low, but it has been noted to occur more frequently in children under 5 years of age and those with pre-existing respiratory conditions.

Severe Cases and Complications



While the vast majority of children with COVID-19 recover without severe complications, certain pediatric populations are at an increased risk for severe manifestations, particularly those with underlying health conditions. Acute respiratory distress syndrome (ARDS), myocardial inflammation, and other complications have been reported, though they remain rare.

One of the most concerning complications in children is Multisystem Inflammatory Syndrome in Children (MIS-C), which typically occurs 2-6 weeks after the initial infection. MIS-C is characterized by fever, rash, gastrointestinal symptoms, and inflammation in multiple organ systems. Although MIS-C is a rare phenomenon, it requires urgent medical attention, as it can lead to severe cardiovascular complications, including myocarditis and shock.

Figure 1: Prevalence of MIS-C in Pediatric COVID-19 Cases

MIS-C Incidence: 4-6% of COVID-positive children

Severity: 60% require intensive care

Mortality: Approximately 1% in MIS-C cases

Risk Factors for Severe Disease

A number of risk factors have been identified for severe COVID-19 in children, including:
Age: Children under 5 years of age are at a higher risk for respiratory complications and hospitalizations.

Comorbidities: Pre-existing conditions like obesity, asthma, and congenital heart defects increase the likelihood of severe illness.

Immune system disorders: Children with immunodeficiencies, whether congenital or acquired, are more susceptible to severe disease progression.

Treatment and Management

Treatment protocols for pediatric COVID-19 patients have evolved as more data became available. Mild cases are typically managed with supportive care, such as hydration and antipyretics, while severe cases may require hospitalization. Children with respiratory failure may need mechanical ventilation or extracorporeal membrane oxygenation (ECMO) in extreme cases.

For MIS-C, treatment generally involves immunomodulatory therapy, such as intravenous immunoglobulin (IVIG) or corticosteroids, alongside supportive care. Early intervention has been shown to significantly improve outcomes for children affected by MIS-C.

Table 2: Treatment Approaches in Pediatric COVID-19 Cases

Treatment	Mild cases(%)	Severe Cases(%)
Supportive care (hydration,rest)	85%	50%
Antipyretics (ACETAMINO PHEN)	40%	55%
Antiviral agents (remdesivir)	5%	25%
IV Immunoglobulin (IVIG)	0%	35%
Corticosteroids	0%	40%

Long-Term Effects (Long COVID) in Children

An emerging concern is the phenomenon of Long COVID, where children experience prolonged symptoms after recovery from the acute phase of the infection. Common long-term symptoms include fatigue, difficulty concentrating, headaches, and joint pain. Though the

prevalence of Long COVID in children is lower than in adults, it is an important aspect of the disease that requires further research.

Conclusions

The vast majority of pediatric COVID-19 cases are mild, with most children recovering without significant complications. However, certain groups of children, particularly those with pre-existing health conditions, remain at higher risk for severe disease and complications, such as MIS-C. Early identification and treatment of these children, as well as the adoption of vaccination and preventive measures, are essential for improving outcomes. Public health strategies must continue to focus on safeguarding vulnerable pediatric populations and ensuring that they have access to timely and effective healthcare.

REFERENCES

1. Рузиева, Н. Х., Джаббарова, Л. А., & Джаббарова, Ю. К. (2021). ПРИЧИНЫ И ПУТИ СНИЖЕНИЯ ПРЕЖДЕВРЕМЕННЫХ РОДОВ С ИСПОЛЬЗОВАНИЕМ МЕЖДУНАРОДНЫХ ПОДХОДОВ. *Re-health journal*, (1 (9)), 14-18.
2. Nazarova, D. E., Ruzieva, N. K., Turbanova, U. V., & Rassadina, M. V. (2021). THE ROLE OF OXIDANT STRESS IN THE DEVELOPMENT OF PREMATURE CHILDBIRTH. *Central Asian Journal of Pediatrics*, 2021(1), 30-36.
3. Рузиева, Н. Х., Джаббарова, Л. А., & Джаббарова, Ю. К. (2021). ПРИЧИНЫ И ПУТИ СНИЖЕНИЯ ПРЕЖДЕВРЕМЕННЫХ РОДОВ С ИСПОЛЬЗОВАНИЕМ МЕЖДУНАРОДНЫХ ПОДХОДОВ. *Re-health journal*, (1 (9)), 14-18.
4. Mukhamedkhanova, S. T., Yuldasheva, D. S., Mirzaev, N. B., Ruzieva, N. K., & Aripova, F. S. (2020). Pathogenesis specifics of allergic reactivity in hypertensive conditions of pregnant. *Indian Journal of Forensic Medicine and Toxicology*, 14(4), 7233-7238.
5. Рузиева, Н. Х., Расул-Заде, Ю. Г., & Алиёрова, Г. А. (2020). A NEW LOOK AT THE PATHOGENETIC MECHANISM, CLINICAL COURSE AND METHODS OF TREATMENT OF PREGNANT WOMEN WITH ARVI. *Новый день в медицине*, (4), 108-114.
6. Ruzieva, N., Nazarova, D. E., Turbanova, U. V., & Rassadina, M. V. (2019). THE ROLE OF OXIDANT STRESS IN THE DEVELOPMENT OF PREMATURE CHILDBIRTH. *Central Asian Journal of Pediatrics*, 2(1), 54-57.
7. Рузиева, Н. Х., & Бектимирова, А. А. (2016). ДРОЖЖЕПОДОБНЫЕ ГРИБЫ РОДА CANDIDA В ГЕНИТАЛЬНОМ ТРАКТЕ ЖЕНЩИН РЕПРОДУКТИВНОГО ВОЗРАСТА. *Редакционная коллегия*, 51.

F.K. Tashpulatova, S.A. Agzamova THE EFFECTIVENESS OF MULTI-COMPONENT ANTI-TUBERCULOSIS DRUGS IN THE TREATMENT OF PULMONARY TUBERCULOSIS.....	133
M. Kadirova, S. Kadirov CLINICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE.....	137
M.S. Akbarova CLINICAL MANIFESTATIONS AND OUTCOMES OF COVID-19 IN PEDIATRIC POPULATIONS: A COMPREHENSIVE REVIEW.....	142
Sh. Marufov DERMATOGLYPHIC ANALYSIS FOR THE EARLY DIAGNOSIS OF TYPE 1 DIABETES IN CHILDREN.....	146
M.M. Ernazarova COMPREHENSIVE INSIGHTS INTO CHRONIC KIDNEY DISEASE IN METABOLIC SYNDROME PATIENTS: MANAGEMENT STRATEGIES AND CLINICAL OUTCOMES.....	149
A.S. Yusupov THE SPREAD OF MEASLES IN UNVACCINATED CHILDREN AND PREVENTIVE MEASURES.....	152
Z.S. Tantosheva, F.A. Babadjanova SLEEP AND ITS IMPACT ON HEALTH.....	156
N.M. Djuraeva, A.I. Ikramov, Z.D. Mirtadzhieva, D.X. Xursanova, D.V. Valizhonova CLINICAL CASE REPORT: REGIONAL HEPATIC STEATOSIS AND ITS DIAGNOSTIC ASPECTS.....	159
O.A. Nazarov, M.N. Abdullayeva FEATURES OF DIAGNOSING CROSS-SENSITIZATION IN CHILDREN WITH ATOPIC DERMATITIS.....	165
Z.Sh. Khidoyatova, A.R. Davletyarova COMPARATIVE ANALYSIS OF METHODS OF LICENSING PHARMACY ACTIVITIES IN RUSSIAN FEDERATION AND UZBEKISTAN.....	170
F.A. Doniyorova FEATURES OF HIGHER CORTICAL ACTIVITY IN CHILDREN WITH AUTISM SPECTRUM DISORDERS.....	174
A.Kh. Rajabov, U.Kh. Umarov MODERN DIAGNOSTIC METHODS FOR PATIENTS WITH CHRONIC TONSILLITIS.....	183
A.N. Akbarov, M.A. Xomidov, G.B. Aslanova RESULTS OF CLINICAL OBSERVATION OF PATIENTS AFTER SURGICAL MANAGEMENT OF PERI-IMPLANT SOFT TISSUE RECESSON WITH HYALURONIC ACID INJECTION GEL CORRECTION.....	188
F. Boltayev, A. Pirkhanov, B. Nizametdinov, K. Umurzokov THE ROLE OF MICROORGANISMS IN HOSPITAL INFECTIONS.....	197
Sh.Yu. Ibodulloyeva FREQUENCY AND CLINICAL VARIANTS OF BILIARY TRACT IN CHILDREN.....	200
Sh.Yu. Ibodullayeva DIAGNOSIS AND STUDY OF CLINICAL FEATURES OF BILIARY TRACT DISEASES IN CHILDREN.....	206
M.B. Devorova, M.I. Shayxova CURRENT THERAPEUTIC STRATEGIES IN THE TREATMENT OF CHILDHOOD ALLERGIC RHINITIS.....	212
A. Sobirova, F.A. Babadjanova THE PHYSIOLOGICAL MECHANISMS OF MEMORY AND AGE-RELATED CHANGES.....	216
Sh.T. Ziyaeva, K.T. Mirzaakhmedova DIAGNOSIS OF IRON DEFICIENCY CONDITIONS AND IRON DEFICIENCY ANEMIA.....	219
S.D. Aminov SEMAGLUTIDE - FOR THE TREATMENT OF OBESITY.....	222
M.N. Buriyev ANALYSIS OF ULTRASOUND EXAMINATION RESULTS OF THE HIP JOINT IN NEWBORNS.....	225
N. Voronina STUDY FEATURES PREVENTION OF THE MICROCLIMATE IN GREENHOUSES WITH PROTECTED SOIL IN UZBEKISTAN.....	229
J.T. Raimjonov CURRENT STATE OF THE SYSTEM FOR IMPROVING THE QUALIFICATIONS OF EMERGENCY MEDICAL SERVICES STAFF.....	233
Z.R. Akhmedova, T.E. Shonahunov, A.A. Ibragimov, G.H. Kadirova, Z.T. Khamraeva, A.I. Komarov, M.A. Yakhyaeva, O.A. Verushkina, I.T. Gulyamova, A.K. Tonkikh DESORPTION OF IMMOBILIZED <i>ESHERICHIA COLI</i> CELLS. <i>PCS. ATCC 25922</i> WITH SOLID ADSORBENTS CREATED WITH VARIOUS FORMS OF ALUMINUM OXIDE.....	236



**International Scientific Journal
Science and Innovation Series D
Volume 4 Issue 2**

ISSN: 2181-3337

Published: 28.02.2025. Font: "Times New Roman".

LLC “Science and innovation”

License Mass Media №:1597 27.04.2022

License Publisher №:455168 21.11.2024

Address: 100121, Uzbekistan, Tashkent city, Yakkasaroy district,
Shota Rustaveli Street 150, Vega Business Center, 6th floor, Room 2.

www.scientists.uz, info@scientists.uz, +998901259654